XML 17 R9.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

During the quarter ended September 30, 2024, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.

 

Character of Trading Arrangement

Name and Title

Action

Date

Rule 10b5-1*

Non-Rule 10b5-1**

Total Shares to be Sold

Expiration Date

Faye M. Feller, M.D.,

Executive Vice President and Chief Medical Officer

Adoption

July 12, 2024

X

974,1671

June 30, 2025

Andrew J. Grethlein, Ph.D.,

Executive Vice President and Chief Operating Officer

Adoption

July 12, 2024

X

 

1,279,9852

November 14, 2025

John A. Scarlett, M.D.,

Chairman of the Board, President and Chief Executive Officer

Adoption

July 12, 2024

X

1,374,2983

July 11, 2025

Anil Kapur

Executive Vice President, Corporate Strategy, and Chief Commercial Officer (until August 31, 2024)

Adoption

July 9, 2024

X

 

1,587,5004

June 27, 2025

* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

** "Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.

1 Consists of 974,167 shares subject to stock options previously granted by Geron to Dr. Feller.

2 Consists of 1,279,985 shares subject to stock options previously granted by Geron to Dr. Grethlein.

 

3 Consists of 1,374,298 shares subject to stock options previously granted by Geron to Dr. Scarlett.

 

4 Mr. Kapur's employment with Geron terminated on August 31, 2024. Consists of 1,587,500 shares subject to stock options previously granted by Geron to Mr. Kapur.
Faye M. Feller, M.D.  
Trading Arrangements, by Individual  
Name Faye M. Feller, M.D.
Title Executive Vice President and Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Non-Rule 10b5-1 Arrangement Adopted false
Adoption Date July 12, 2024
Expiration Date June 30, 2025
Arrangement Duration 354 days
Aggregate Available 974,167 [1]
Andrew J. Grethlein, Ph.D.  
Trading Arrangements, by Individual  
Name Andrew J. Grethlein, Ph.D.
Title Executive Vice President and Chief Operating Officer
Rule 10b5-1 Arrangement Adopted true
Non-Rule 10b5-1 Arrangement Adopted false
Adoption Date July 12, 2024
Expiration Date November 14, 2025
Arrangement Duration 491 days
Aggregate Available 1,279,985 [2]
John A. Scarlett, M.D.  
Trading Arrangements, by Individual  
Name John A. Scarlett, M.D.
Title Chairman of the Board, President and Chief Executive Officer
Rule 10b5-1 Arrangement Adopted true
Non-Rule 10b5-1 Arrangement Adopted false
Adoption Date July 12, 2024
Expiration Date July 11, 2025
Arrangement Duration 365 days
Aggregate Available 1,374,298 [3]
Anil Kapur  
Trading Arrangements, by Individual  
Name Anil Kapur
Title Executive Vice President, Corporate Strategy, and Chief Commercial Officer
Rule 10b5-1 Arrangement Adopted true
Non-Rule 10b5-1 Arrangement Adopted false
Adoption Date July 9, 2024
Expiration Date June 27, 2025
Arrangement Duration 354 days
Aggregate Available 1,587,500 [4]
[1] Consists of 974,167 shares subject to stock options previously granted by Geron to Dr. Feller.
[2] Consists of 1,279,985 shares subject to stock options previously granted by Geron to Dr. Grethlein.
[3] Consists of 1,374,298 shares subject to stock options previously granted by Geron to Dr. Scarlett.
[4] Mr. Kapur's employment with Geron terminated on August 31, 2024. Consists of 1,587,500 shares subject to stock options previously granted by Geron to Mr. Kapur.